1 |
Ohtsu H, Suzuki H, Nakashima H, et al. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 2006; 48:534-40
DOI
ScienceOn
|
2 |
Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006;98:887-96
DOI
ScienceOn
|
3 |
Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-91
|
4 |
Kim KB. The role of angiotensin receptor antagonist in patients with hypertension and cardiovascular diseases. Korean Circ J 1999;29:335-40
DOI
|
5 |
Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens Suppl 2005;23:S9-17
DOI
|
6 |
Weber MA. Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens Suppl 2006;24:S37-44
DOI
|
7 |
Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006;98:463-71
DOI
ScienceOn
|
8 |
Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997;80: 607-16
DOI
ScienceOn
|
9 |
Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668-76
DOI
ScienceOn
|
10 |
Wolf G, Wenzel UO. Angiotensin II and cell cycle regulation. Hypertension 2004;43:693-8
DOI
ScienceOn
|
11 |
Kim YH, Son JH, Piao H, et al. Role of angiotensin II type 1A receptor-mediated signaling in the development of pressure overload- induced left ventricular hypertrophy and fibrosis. Korean Circ J 2006;36:626-34
DOI
|
12 |
Kim KM, Kim IS, Park SJ, et al. Effects of angiotensin II on the growth of vascular smooth muscle cells. Korean Circ J 1999;29: 209-15
DOI
|
13 |
Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006;113:2851-60
DOI
ScienceOn
|
14 |
Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, Alexander RW. cAbl tyrosine kinase mediates reactive oxygen species and caveolin-dependent receptor signaling in vascular smooth muscle. Circ Res 2005;97:829-36
DOI
ScienceOn
|
15 |
Rosendorff C. Vascular hypertrophy in hypertension: role of the renin-angiotensin system. Mt Sinai J Med 1998;65:108-17
|
16 |
Schulman IH, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. Hypertension 2007;49:270-1
DOI
ScienceOn
|
17 |
Mancia G. Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 2006;24:S17-24
DOI
|
18 |
Yang CH, Lee SH, Park TH, et al. Gene expression profile of volume-overloaded human ventricular myocardium prior to developing heart failure. Korean Circ J 2005;35:649-57
DOI
|
19 |
Hollenberg NK. Hypertension, small arteries, and pathways for angiotensin II generation. Circulation 2000;101:1641-2
DOI
ScienceOn
|
20 |
Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24:11-25
DOI
ScienceOn
|
21 |
Sokol SI, Portnay EL, Curtis JP, et al. Modulation of the reninangiotensin- aldosterone system for the secondary prevention of stroke. Neurology 2004;63:208-13
DOI
ScienceOn
|
22 |
Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived . Hypertension 2005;46:732-7
DOI
ScienceOn
|
23 |
Jeon ES. Role of angiotensin II receptor blockers in the treatment of congestive heart failure. Korean Circ J 2002;32:1039-45
DOI
|
24 |
Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996;28:803-12
DOI
ScienceOn
|
25 |
Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens 2007;25:25-35
DOI
ScienceOn
|
26 |
Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikreinkinin systems. Hypertension 2005;46:1236-42
DOI
ScienceOn
|
27 |
Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE, Berk BC. Angiotensin II signal transduction and the mitogenactivated protein kinase pathway. Cardiovasc Res 1995;30:511-7
DOI
|
28 |
Diez J. Profibrotic effects of angiotensin II in the heart. Hypertension 2004;43:1164-5
DOI
ScienceOn
|
29 |
Ulfendahl HR, Aurell M. Renin-Angiotensin: a centenary symposium of the discovery of the renin-angiotensin system. London: Portland Press; 1998. p.1-12
|
30 |
Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005;23:S27-33
DOI
|
31 |
Smith NJ, Luttrell LM. Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease. Hypertension 2006;48:173-9
DOI
ScienceOn
|
32 |
Calo LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone: evidence from studies in humans. J Hypertens 2007;25:259-64
DOI
ScienceOn
|
33 |
Unger T, Culman J, Peter G. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998;16:S3-9
DOI
ScienceOn
|
34 |
Alfakin K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006; 24:1223-30
DOI
ScienceOn
|
35 |
Farmer JA. Renin angiotensin system and ASCVD. Curr Opin Cardiol 2000;15:141-50
DOI
ScienceOn
|
36 |
Pan L, Gross KW. Transcriptional regulation of renin. Hypertension 2005;45:3-8
DOI
|
37 |
Sampaio WO, Souza dos Santos RA, Faria-Silva R, de Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185-92
DOI
ScienceOn
|
38 |
Suh SY, Park CG, Chwe UR, et al. Plasma renin activity and clinical implication in Korean hypertensive patients. Korean Circ J 2005;35:658-64
DOI
|
39 |
Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
DOI
ScienceOn
|
40 |
de Leeuw PW. How do angiotensin II receptor antagonists affect blood pressure? Am J Cardiol 1999;84:5K-6K
DOI
ScienceOn
|
41 |
Willenheimer R, Dahloef B, Rydberg E, Erhardt L. AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999;20:997-1008
DOI
ScienceOn
|
42 |
Sleight P, Yusuf S. New evidence on the importance of the reninangiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003;21:1599-608
DOI
ScienceOn
|
43 |
Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006;98:1123-33
DOI
ScienceOn
|
44 |
Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20
DOI
ScienceOn
|
45 |
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6
DOI
ScienceOn
|
46 |
Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005;97: 434-42
DOI
ScienceOn
|
47 |
Beierwaltes WH. Renin synthesis and secretion. In: Izzo JL, Black HR, editor. Hypertension Primer. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p.14-7
|
48 |
Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DCPI) (dipeptidyl carboxypeptidase I). Nucleic Acids Res 1992;20:1433
|
49 |
Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998;16:S23-9
DOI
ScienceOn
|
50 |
Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens 2001;10:617-24
DOI
ScienceOn
|
51 |
Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Phamacol 2002; 39:319-27
DOI
ScienceOn
|